MEDINDIA
English
हिन्दी
Español
français
中文
The French drug maker obtained the license for the Multiple Sclerosis drug, Vatelizumab, from Glenmark in a $600 million deal in 2011.
Sanofi Recalls Thousands of Auvi-Q Epinephrine Autoinjectors from US and Canada
The drug firm voluntarily recalled the devices after dose-dispensing problems were identified in internal quality reviews and after 26 reports from consumers.
The drug firm voluntarily recalled the devices after dose-dispensing problems were identified in internal quality reviews and after 26 reports from consumers.
“Sanofi’s decision was not due to any safety concerns, we will continue to pursue the relicensing of GBR 500 after it’s returned from Sanofi,” said Glenmark.
The drug candidate is believed to block VLA-2 on activated immune cells, leading to interference with collagen-binding in areas of inflammation and thus may reduce the inflammatory cascade in MS, reasoned Glenmark and Genzyme, a Sanofi company.
Sanofi�s New Chief Executive Set To Deliver Strategic Plan After Falling Diabetes Sales
The company has other strategic commercial launches it needs to succeed with, such as an anti-cholesterol drug, Praluent that was approved in the US and the European Union.
The company has other strategic commercial launches it needs to succeed with, such as an anti-cholesterol drug, Praluent that was approved in the US and the European Union.
Sanofi�s New Diabetes Drug LixiLan Shows Promising Results in Phase III Trial
Sanofi, a global healthcare leader, has announced that a second late-stage Phase III study of its LixiLan diabetes drug had met its main target.
Sanofi, a global healthcare leader, has announced that a second late-stage Phase III study of its LixiLan diabetes drug had met its main target.
Legal Options Are Being Evaluated By Glenmark After Its Diabetes Drug Setback
MerckSharp in its plea had sought injunction against Glenmark alleging that the Indian pharma company had violated its IPR over its anti-diabetes drugs.
MerckSharp in its plea had sought injunction against Glenmark alleging that the Indian pharma company had violated its IPR over its anti-diabetes drugs.
Email
